Retinitis Pigmentosa Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Retinitis Pigmentosa Patients
Conditions: Retinitis Pigmentosa Sponsors: Ray Therapeutics, Inc.; The Vision Research and Assessment Institute (VRAI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials

Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa Sponsors: University Hospital Tuebingen Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
Conditions: X-Linked Retinitis Pigmentosa Interventions: Biological: rAAV2tYF-GRK1-RPGR Sponsors: Beacon Therapeutics Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials

Natural History Study in Patients With PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa Sponsors: University Hospital Tuebingen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials

The Effects of Disulfiram (Antabuse ®) on Visual Acuity in Patients With Retinal Degeneration
Conditions: Alcohol Use Disorder; Retinal Dystrophies; Age-Related Macular Degeneration; Retinitis Pigmentosa; Stargardt Disease Interventions: Drug: Oral disulfiram Sponsors: University of Rochester Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials

Biomarkers in Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa Interventions: Diagnostic Test: OCT, OCT angiography, flicker ERG and Ultra Wide Field retinography and autofluorescence. Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
Conditions: Retinitis Pigmentosa Interventions: Drug: ZM-02-L; Drug: ZM-02-H; Procedure: ZM-02-S Sponsors: Zhongmou Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 5, 2024 Category: Research Source Type: clinical trials

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
Conditions: Retinitis Pigmentosa Interventions: Drug: VG901 Sponsors: ViGeneron GmbH Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials

DAWN: A Phase 2 Multi-center Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Who Have Been Previously Treated With an AAV Vector-based Gene Therapy Designed to Provide Full-length Functioning RPGR Protein
Conditions: X-Linked Retinitis Pigmentosa Interventions: Biological: AGTC-501 (high dose and standard corticosteroid regimen); Biological: AGTC-501 (low dose and standard corticosteroid regimen); Biological: AGTC-501 (high dose and modified corticosteroid regimen) Sponsors: Beacon Therapeutics Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials

Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa
London, UK, Cambridge, MA, 08 February 2024– Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or‘the Company’), a leading ophthalmic gene therapy company with a mission to save and restore the vision of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 8, 2024 Category: Pharmaceuticals Source Type: clinical trials

Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa Interventions: Biological: GMP compliant-BM-MSC derived sEVs Sponsors: Mahidol University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials

Transpalpebral electrical stimulation for the treatment of retinitis pigmentosa: study protocol for a series of N-of-1 single-blind, randomized controlled trial
DiscussionThe trial will evaluate the efficacy and safety of microcurrent stimulation on RP and provide high-quality evidence for clinical application through N-of-1 trial.Trial registrationChinese Clinical Trial Registry; ChiCTR2300067357;https://www.chictr.org.cn/showproj.html?proj=174635. Registered on 5 January 2023 (Source: Trials)
Source: Trials - January 27, 2024 Category: Research Source Type: clinical trials

Coloured-light in Retinitis Pigmentosa.
Conditions: Retinitis Pigmentosa Interventions: Device: Coloured-light torch; Device: Different coloured-light torch Sponsors: University College, London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Conditions: Retinitis Pigmentosa; Retinitis; Retinal Diseases; Eye Diseases; Eye Diseases, Hereditary; Retinal Dystrophies; Retinal Degeneration Interventions: Biological: Gene Therapy product-MCO-010 Sponsors: Nanoscope Therapeutics Inc. Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials

Evaluation of New Head-mounted Visual Aids Among Patients With Low Vision
Conditions: Glaucoma; Age-related Macular Degeneration; Retinitis Pigmentosa; Diabetic Retinopathy Interventions: Device: New head-mounted visual aids Sponsors: Zhongshan Ophthalmic Center, Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials